Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.

Landy SH, Turner IM, Runken MC, Lee M, Sulcs E, Bell CF.

Headache. 2013 Jul-Aug;53(7):1134-46. doi: 10.1111/head.12140. Epub 2013 Jun 14.

PMID:
23773016
[PubMed - indexed for MEDLINE]
2.

Acute migraine treatment with oral triptans and NSAIDs in a managed care population.

Ng-Mak DS, Hu XH, Chen YT, Ma L.

Headache. 2008 Sep;48(8):1176-85.

PMID:
18819177
[PubMed - indexed for MEDLINE]
3.

Examining the interrelationship of migraine onset, duration, and time to treatment.

Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS.

Headache. 2012 Mar;52(3):363-73. doi: 10.1111/j.1526-4610.2011.02029.x. Epub 2011 Nov 11.

PMID:
22077159
[PubMed - indexed for MEDLINE]
4.

Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.

Holland S, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB.

J Neurol Sci. 2013 Mar 15;326(1-2):10-7. doi: 10.1016/j.jns.2012.12.020. Epub 2013 Feb 8.

PMID:
23394974
[PubMed - indexed for MEDLINE]
5.

Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV.

MacGregor EA, Brandes J, Gendolla A, Giammarco R.

Curr Med Res Opin. 2004 Nov;20(11):1777-83.

PMID:
15537478
[PubMed - indexed for MEDLINE]
6.

Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.

Gershovich OE, Billups SJ, Delate T, Hoffman CK, Carroll N.

J Manag Care Pharm. 2006 Apr;12(3):246-53.

PMID:
16623609
[PubMed - indexed for MEDLINE]
Free Article
8.

How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.

Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW, McCrory D, Liberman JN, Williams P.

Curr Med Res Opin. 2005 Mar;21(3):413-24.

PMID:
15811210
[PubMed - indexed for MEDLINE]
9.

Effects of switching acute treatment on disability in migraine patients using triptans.

Serrano D, Buse DC, Kori SH, Papapetropoulos S, Cunanan CM, Manack AN, Reed ML, Lipton RB.

Headache. 2013 Oct;53(9):1415-29. doi: 10.1111/head.12164. Epub 2013 Jun 28.

PMID:
23808937
[PubMed - indexed for MEDLINE]
10.

Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.

Cady R, Martin V, Adelman J, Diamond M, Sajjan S, Hu XH.

Headache. 2004 Oct;44(9):900-7.

PMID:
15447699
[PubMed - indexed for MEDLINE]
11.

Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.

Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB.

Headache. 2012 Feb;52(2):213-23.

PMID:
22413150
[PubMed - indexed for MEDLINE]
12.

A 3-month analysis of disability, quality of life, and disease course in patients with migraine.

Raggi A, Leonardi M, Bussone G, D'Amico D.

Headache. 2013 Feb;53(2):297-309. doi: 10.1111/j.1526-4610.2012.02279.x. Epub 2012 Oct 24.

PMID:
23094760
[PubMed - indexed for MEDLINE]
13.

Education and decision making at the time of triptan prescribing: patient expectations vs actual practice.

Mathew PG, Pavlovic JM, Lettich A, Wells RE, Robertson CE, Mullin K, Charleston Iv L, Dodick DW, Schwedt TJ.

Headache. 2014 Apr;54(4):698-708. doi: 10.1111/head.12308. Epub 2014 Feb 11.

PMID:
24512184
[PubMed - in process]
14.

Identifying the factors underlying discontinuation of triptans.

Wells RE, Markowitz SY, Baron EP, Hentz JG, Kalidas K, Mathew PG, Halker R, Dodick DW, Schwedt TJ.

Headache. 2014 Feb;54(2):278-89. doi: 10.1111/head.12198. Epub 2013 Sep 3.

PMID:
24001117
[PubMed - in process]
15.

Usage of triptans among migraine patients: an audit in nine GP practices.

Williams D, Cahill T, Dowson A, Fearon H, Lipscombe S, O'Sullivan E, Rees T, Strang C, Valori A, Watson D.

Curr Med Res Opin. 2002;18(1):1-9.

PMID:
11999139
[PubMed - indexed for MEDLINE]
16.

Triptan education and improving knowledge for optimal migraine treatment: an observational study.

Baron EP, Markowitz SY, Lettich A, Hastriter E, Lovell B, Kalidas K, Dodick DW, Schwedt TJ; American Headache Society Headache Fellows Research Consortium.

Headache. 2014 Apr;54(4):686-97. doi: 10.1111/head.12286. Epub 2014 Feb 12.

PMID:
24520930
[PubMed - in process]
17.

Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.

Ng-Mak DS, Chen YT, Ho TW, Stanford B, Roset M.

Cephalalgia. 2012 Sep;32(12):875-87. doi: 10.1177/0333102412449929. Epub 2012 Jul 24.

PMID:
22833612
[PubMed - indexed for MEDLINE]
18.

Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.

MacGregor EA, Brandes J, Eikermann A.

Headache. 2003 Jan;43(1):19-26.

PMID:
12864754
[PubMed - indexed for MEDLINE]
19.

Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.

Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML.

Headache. 2013 Nov-Dec;53(10):1548-63. doi: 10.1111/head.12201. Epub 2013 Aug 28.

PMID:
23992516
[PubMed - indexed for MEDLINE]
20.

Applying the benefits of the AwM study in the clinic.

Dodick DW.

Cephalalgia. 2008 Sep;28 Suppl 2:42-9. doi: 10.1111/j.1468-2982.2008.01690.x. Review.

PMID:
18715332
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk